FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

31 letters match. Newest first.

  1. Sanrace Biotechnology Co., Ltd.

    FDA warns Sanrace Biotechnology over CGMP failures in OTC drugs, including missing identity tests and no process validation.

    High risk
  2. Olympus Medical Systems Corporation

    FDA warns Olympus over quality-system failures across six medical device plants, including unvalidated designs and released nonconforming devices.

    High risk
  3. Silgan Dispensing Systems

    Silgan Unicep Packaging was cited for manufacturing quality failures and unapproved new drugs after invalidated microbial tests and a fungal recall.

    High risk
  4. PLZ Corp

    FDA warned PLZ Corp over an OTC talc drug made in Mississauga without asbestos testing and with deficient component controls.

    High risk
  5. Medical Products Laboratories, Inc.

    Medical Products Laboratories was cited for manufacturing failures and selling unapproved prescription skin drugs.

    High risk
  6. MedClub by Dr. Jenn

    FDA warns MedClub by Dr. Jenn over unapproved compounded retatrutide and misleading semaglutide claims on its website.

    High risk
  7. Amneal Pharmaceuticals, LLC

    FDA warns Amneal over visible particles in ropivacaine injection and inadequate investigations and endotoxin lab controls.

    High risk
  8. Macsen Drugs

    FDA cites Macsen Drugs for releasing fire-exposed APIs and inadequate stability data at India plant.

    High risk
  9. O3UV, LLC

    FDA warns O3UV that its Champion and EBOO ozone/UV blood devices are unapproved, misbranded, and made without required quality controls.

    High risk
  10. Huangshi Hygienic Material Medicine Co., Ltd.

    Huangshi Hygienic Material Medicine released U.S. drugs without identity and strength testing and lacked stability data for labeled expiration dates.

    High risk
  11. Wuxi Medical Instrument Factory Co., Ltd.

    FDA warns Wuxi Medical Instrument Factory over insanitary conditions and manufacturing failures for sterile drugs.

    High risk
  12. XO Biologix, LLC

    XO Biologix markets MaviX, an amniotic-fluid product, as an unapproved new drug and unlicensed biologic.

    High risk
  13. Owens & Minor, Inc. dba American Contract Systems, Inc.

    FDA warned Owens & Minor unit American Contract Systems over device quality-system violations for sterile kits, including failed sterilization bags and incomplete design verification.

    High risk
  14. Analytical Food Laboratories, Inc.

    FDA warned contract testing lab Analytical Food Laboratories after inspection found unvalidated drug test methods and weak quality oversight.

    High risk
  15. Nomida.biz

    FDA warned Nomida.biz over its website selling unapproved and misbranded semaglutide and tirzepatide drugs to U.S. consumers.

    High risk
  16. Laboratorio Magnachem International

    FDA cited Laboratorio Magnachem for CGMP failures and unapproved, misbranded Broncochem cough/cold drugs after a 2023 inspection.

    High risk
  17. Prime Lab LLC

    Prime Lab LLC failed U.S. drug manufacturing quality rules for over-the-counter hand soaps and sanitizers, including raw-material testing and shared toxic equipment.

    High risk
  18. Cipla Limited

    FDA warned Cipla about unresolved albuterol inhaler delivery complaints and contamination in sterile manufacturing at its Indore site.

    High risk
  19. Carolina Infusion

    FDA warns Carolina Infusion over compounded drugs made without valid prescriptions and under insanitary conditions, including sterile products.

    High risk
  20. Abbott Point of Care Canada Limited

    FDA says Abbott Point of Care Canada marketed modified i-STAT cTnI cartridges without required FDA clearance.

    High risk
  21. Profounda, Inc.

    FDA warns Profounda about manufacturing quality failures for over-the-counter drugs, including process validation, stability, water system, and glycerin testing.

    High risk
  22. Optum Infusion Services 308 LLC

    FDA warned Optum Infusion Services 308 LLC about insanitary conditions in sterile drug compounding after inspection found vermin and microbial contamination.

    High risk
  23. Turkuaz Sağlik Hizmetleri Medikal Temizlik Kimyasa

    FDA warns Turkish ultrasound gel maker Turkuaz over broad quality-system violations found in 2022 inspection.

    High risk
  24. Age Management Institute Santa Barbara

    FDA cited Age Management Institute Santa Barbara for insanitary sterile compounding of IV drugs, including dirty equipment and expired ingredients.

    High risk
  25. Infusion Options, Inc.

    FDA found Infusion Options produced sterile compounded drugs under insanitary conditions and failed 503B labeling and reporting rules.

    High risk
  26. CellEra LLC

    CellEra LLC's sterile silver wound dressings have repeated quality-system violations and uncleared labeling claims, FDA says.

    High risk
  27. Maitland Labs of Central Florida

    FDA warns Maitland Labs of Central Florida over sterile compounded drugs with manufacturing quality failures, mislabeling, and unapproved new drug violations.

    High risk
  28. Nikkiso Medical America, Inc

    FDA warns Nikkiso Medical America that its DBB-06 dialysis device with unapproved automated blood-volume control is adulterated and misbranded.

    High risk
  29. Joe Wise Pharmacy, Inc., dba Wise Pharmacy

    FDA warned Wise Pharmacy that its compounded sterile and non-sterile drugs were adulterated by insanitary compounding conditions.

    High risk
  30. American Specialty Pharmacy, Inc. dba ASP Cares

    FDA warned outsourcing facility ASP Cares about sterile compounded drugs made under insanitary conditions and with CGMP violations.

    High risk
  31. Allay Pharmaceuticals, LLC

    FDA warned Allay Pharmaceuticals over CGMP failures and sub-potent tablets, and distribution of an unapproved biological product.

    High risk